R Tyler Hillman, MD, PhD, on Important Contributors Needed to Treat Ovarian Granulosa Cell Tumors

Video

An expert emphasizes how a big team is needed to properly employ the different therapeutic modalities needed to treat patients with ovarian granulosa cell tumors.

R Tyler Hillman, MD, PhD, of The University of Texas MD Anderson Cancer Center in Houston, spoke with CancerNetwork® at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting about various clinicians from the multidisciplinary care team necessary to properly treat patients with ovarian granulosa cell tumors.

Transcription:

It takes a big team for these patients because we often employ a variety of different therapeutic modalities. In the recurrent setting, which is predominantly where I see and treat granulosa cell tumors, frequently, we’re using cytoreductive surgery as the mainstay. The key to enhanced recovery from these surgeries involves nutritionists, and floor and [operating room nurses]. And then our advanced practice providers in the clinic provide a lot of the counseling and preoperative preparation to get folks ready for the OR. It’s all especially important because we often combine surgery with adjuvant treatments, so the recovery from surgery impacts how soon we're able to start—whether it's chemotherapy or hormonal therapy—in the adjuvant setting.

Reference

Hillman RT, Lin DI, & Gershenson DM. Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors. J Clin Oncol 39, 2021 (suppl 15; abstr 5567). 10.1200/JCO.2021.39.15_suppl.5567

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content